Zacks.com Sales of Edaravone injection decreased 10.3% year over year primarily due to pricing restrictions by the government along with issues relating to the tendering process. Cancer drug Sinofuan (declined 16.9% in terms of local currency) also performed ... and more »
Seeking Alpha Impacted by government pricing restrictions and issues relating to the tendering process, sales of Edaravone in Q1 2013 were RMB 144 million. This represents a decrease of 10.3% versus the same period in 2012 and a decrease of 21.9% compared with Q4 ... and more »
NASDAQ Sales of Edaravone injection decreased 10.3% year over year primarily due to pricing restrictions by the government along with issues relating to the tendering process. Cancer drug Sinofuan (declined 16.9% in terms of local currency) also performed ... and more »
